[Dacarbazine in malignant melanoma. Rare, severe side-effect: Budd-Chiari-syndrome (author's transl)].
Dacarbazine (DTIC) alone or in combination with other cytostatic drugs may lead to severe liver disease with acute thrombosis of intrahepatic veins and parenchymal cell necrosis. 6 such cases were described in the literature, an additional case is described here, all with fatal outcome. 6 of these 7 patients had malignant melanoma. The disease has been partly designed as Budd-Chiari-Syndrome (BCS), partly as veno-occlusive disease (VOD).-The pathoanatomical findings and the appearance of the clinical symptoms exclusively during the 2nd injections series suggest a Budd-Chiari-Syndrome, in terms of an allergic-hyperergic reaction of the liver as target organ. For future administration of Dacarbazine in malignant melanoma (a) patients with pre-existent liver disease should be excluded from DTIC-treatment, (b) the prodromi and cardinal symptoms should be carefully registered and (c) high dosage corticosteroid therapy with fibrinolytic measures should be immediately administered.
D006502:Budd-Chiari Syndrome / Q000139:chemically induced* / Q000473:pathology; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008099:Liver / Q000473:pathology; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy*
D003606:Dacarbazine
DTIC bei Malignem Melanom. Seltene, schwere Komplikation: Budd-Chiari-Syndrom.